Abstract
Reverse transcription–quantitative polymerase chain reaction (RT-qPCR) is used worldwide to test and trace the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). “Extraction-less” or “direct” real time–reverse transcription polymerase chain reaction (RT-PCR) is an open-access qualitative method for SARS-CoV-2 detection from nasopharyngeal or oral pharyngeal samples with the potential to generate actionable data more quickly, at a lower cost, and with fewer experimental resources than full RT-qPCR. This study engaged 10 global testing sites, including laboratories currently experiencing testing limitations due to reagent or equipment shortages, in an international interlaboratory ring trial. Participating laboratories were provided a common protocol, common reagents, aliquots of identical pooled clinical samples, and purified nucleic acids and used their existing in-house equipment. We observed 100% concordance across laboratories in the correct identification of all positive and negative samples, with highly similar cycle threshold values. The test also performed well when applied to locally collected patient nasopharyngeal samples, provided the viral transport media did not contain charcoal or guanidine, both of which appeared to potently inhibit the RT-PCR reaction. Our results suggest that open-access, direct RT-PCR assays are a feasible option for more efficient COVID-19 coronavirus disease testing as demanded by the continuing pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding A grant from the Health and Environmental Sciences Institute to the University of Washington supported preparation and shipment of Part A and B samples to Propagate partner laboratories. Fondecyt 1201240 provided funding for the work of C Vial and P Vial. Grant numbers 5R01AI129518 and UM1AI068635, and a gift from the MJ Murdock Charitable Trust helped to support the work of University of Washington and Fred Hutchinson Cancer Research Center researchers.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The samples generated and disseminated as part of Projects A and B were approved under a waiver of consent by the University of Washington institutional review board (IRB; STUDY00000408). The de-identified samples were determined to be exempt because they were not considered human subjects research due to the quality improvement and public health intent of the work. For Project C, participating laboratories sought the locally appropriate review and permissions for use of de-identified clinical samples as described below. University of West Indies: Based on the Campus Research Ethics Committee at the University of West Indies, this research met the criteria for Exemption. This decision was made by the chair of the ethics committee, Professor Jerome De Liste. Department of Infectious Diseases, Institute of Tropical Medicine of Sao Paulo: Sample use was approved by the local ethics committee (Comissao de Etica para Analise de Projeto de Pesquisa; protocol number CAAE 30419320.7.0000.0068). Informed consent was obtained from all the individuals enrolled in this study. National Veterinary Research Institute, Nigeria: This work and samples were approved for ethical use within the emergency response to COVID-19 control in Nigeria through rapid laboratory diagnosis. The National Veterinary Research Institute in accordance with the World Organization for Animal Health guidance offered its facility for Public Health Service in Nigeria following activation by the Nigerian Centre for Diseases Control of the Federal Ministry of Health. University of Malawi: Based on a review by the College of Medicine Research and Ethics Committee (COMREC), no IRB approval acknowledgments were required. This was reviewed by the COMREC administrator, Dr. Lucinda Manda-Taylor, and the compliance officer, Khama Mita. University of Vermont: This work was approved under a waiver of consent by the University of Vermont IRB (STUDY00000881). Instituto de Ciencias e Innovacion en Medicina, Facultad de Medicina Clinica Alemana Universidad del Desarrollo, Santiago, Chile: The study and publication of its data was approved by a decision made by the Scientific Ethics Committee at the Center of Bioethics at the College of Medicine on 17 March 2021 (as approved by Dr. Marcial Osorio (President of the Scientific Ethics Committee) and Javiera Bellolio A. (Executive Secretary of the Scientific Ethics Committee, College of Medicine, Center of Bioethics) upon review of the document (Admin_Comp_200-53 Requests for Release of Clinical Specimens or Results), as well as this manuscript. The committee made the statement (It is considered that, given the modality of the study, where the identity is duly protected, and, given the importance from the public health point of view, this project has been approved by the Committee for the publication of the data.) The signed document can be provided upon request. Bauru School of Dentistry, Department of Biological Sciences, University of Sao Paulo: Sample use approved by the Institutional Review Board of the Bauru School of Dentistry, University of Sao Paulo (CAAE # 32658720.4.0000.5417)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Affiliations were corrected for Authors from Scientific Platform Pasteur-USP, Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil.
Data Availability
Data can be provided from authors upon request.
Abbreviations
- CDC
- Centers for Disease Control and Prevention
- COVID-19
- coronavirus disease
- Ct
- cycle threshold
- FFU
- focus forming unit
- HESI
- Health and Environmental Sciences Institute
- IRB
- institutional review board
- N2
- specific PCR target within SARS-CoV-2 nucleocapsid (N) gene
- RNA
- ribonucleic acid
- RP
- human RNase P gene
- RT-PCR
- real time–reverse transcription polymerase chain reaction
- RT-qPCR
- reverse transcription–quantitative polymerase chain reaction
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- UWVL
- University of Washington Virology Laboratory
